Close

Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.

×

Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

Theranos further restructures its board, operations

Jaclyn Jaeger | May 12, 2016

Theranos yesterday made further changes to board of directors, as the ailing biotech start-up faces civil and criminal investigation into whether it defrauded investors. The company also announced the retirement of Sunny Balwani as president and chief operating officer.

The latest additions to Theranos’ board include Fabrizio Bonanni, retired in 2013 from his position as executive vice president at independent biotechnology company Amgen. In his 14 years with Amgen, Bonanni, served in numerous roles, including as senior vice president, quality and compliance and corporate compliance officer; senior vice president, manufacturing; and executive vice president, operations, overseeing the company’s global production and supply chain activities, as well as quality, process development, drug delivery devices, engineering, and environment, health...

Read this single article for $49, or click the subscribe button below to review subscription options.

Enjoy unlimited access to thousands of articles, browse five years of digital magazines, qualify for reduced admission to events, and more.